A recent study out of Johns Hopkins shows that a new and simple grading system may be effective for predicting outcomes in men with prostate cancer. In fact, the researchers say the test — in an analysis of 20,000 men — appears to be an improvement over the Gleason grading system, the current standard. Read the article.
New Prostate Cancer Grading System Found Superior to Gleason System Read More »
Health of more than 26,000 men, aged over 30, was tracked for five years. Avoiding all animal-related foods cut odds of the cancer by 35 per cent. Those who ate eggs and dairy just as likely to get disease as meat eaters Read the article.
Going VEGAN slashes the risk of prostate cancer by a third Read More »
The results of a study support an association between the use of androgen deprivation therapy (ADT) in the treatment of prostate cancer and an increased risk of Alzheimer’s disease in a general population cohort. Read the article.
Common prostate cancer treatment may double Alzheimer’s risk Read More »
A 2013 study published in the International Journal of Cancer raises concerns about alcohol’s ability to throw off prostate cancer tests. The investigators found a modestly higher risk of prostate cancer among heavy drinkers; they also observed evidence of lower PSA levels associated with increasing consumption of alcohol. This means it can be more difficult to detect prostate cancer using PSA levels among men who are heavy drinkers. In an older study of Harvard alumni, researchers concluded wine or beer consumption was unassociated with prostate cancer; however, moderate liquor consumption was associated with a significant 61-67 percent increased risk of
Alcohol, especially liquor, increases prostate risk and skews PSA Read More »
The optimal treatment of clinically localized prostate cancer is controversial. Most studies focus on biochemical (PSA) failure when comparing radical prostatectomy (RP) with radiation therapy (RT), but this endpoint has not been validated as predictive of overall survival (OS) or cause-specific survival (CSS) The available literature was analyzed to determine whether reliable conclusions could be made concerning the effectiveness of RP compared with RT with or without androgen deprivation therapy (ADT). Reliable evidence that RP provides a superior CSS to RT with ADT is lacking. The most reliable studies suggest that the differences in 10-year CSS between RP and RT
The treatment uses a virus hidden in immune cells that seek and destroy cancer cells from within. Trials on rodents have cured cancerous growths and were alive and cancer free at the end of the 40 day study. Fifteeen British men are to start a clinical trial using the technique – the first time it has been tested in humans. Read the article.
New Cancer treatment promises to ‘obliterate’ tumours Read More »
MRF-TB (magnetic resonance imaging-ultrasound fusion targeted prostate biopsy) may improve the detection of prostate cancer in men presenting for prostate biopsy. In men presenting for primary prostate biopsy MRF-TB detects more high grade cancers than systematic biopsy. Most cancers detected by systematic biopsy and not by MRF-TB are at clinically low risk. Prebiopsy magnetic resonance imaging followed by MRF-TB decreases the detection of low risk cancers while significantly improving the detection and risk stratification of high grade disease. Read the article.
MRI-Ultrasound Fusion Biopsy Detects High-Grade Prostate Cancer Read More »
Traditional methods of treating prostate cancer, which attack the whole prostate with radiation or surgery, often come at the cost of the patient’s continence or erectile function. A new, less-invasive technology for getting rid of prostate cancer, known as the “nanoknife”, targets only the site of the cancer, destroying the cells of the cancer without the structures surrounding it, including the erectile and urethral nerves. In a study of 25 patients, in 76 per cent of cases the cancer had not returned after eight months. None of them developed incontinence or impotence. Read the article.
Prostate cancer patients zapped with electricity in new treatment Read More »
Dr. Eleftherios Diamandis, a researcher at Toronto’s Mount Sinai Hospital, would like a better alternative that could reduce unnecessary biopsies. Dr. Diamandis plans to spend the next two years developing a non-invasive test that can help determine when high PSA levels warrant concern. To do this, he will zero in on genetic mutations found in the semen of men with prostate cancer and use those biomarkers to screen other men for the disease. Read the article.
Semen-based test for diagnosing prostate cancer could reduce unnecessary biopsies Read More »
A study from Karolinska Institutet in Sweden shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA. The new test, which has undergone trial in 58,818 men, discovers aggressive cancer earlier and reduces the number of false positive tests and unnecessary biopsies. Read the article.
New test for prostate cancer significantly improves prostate cancer screening Read More »